Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Hepatology International
Published in: Hepatology International 4/2012

01-10-2012 | Review Article

Systematic review: extracorporeal bio-artificial liver-support system for liver failure

Authors: Jinyang Gu, Xiaolei Shi, Haozhen Ren, Qingxiang Xu, Jun Wang, Jiangqiang Xiao, Yitao Ding

Published in: Hepatology International | Issue 4/2012

Login to get access

Abstract

Background

Orthotopic liver transplantation (OLT) is the only effective long-term treatment for liver failure by now. However, it is not yet a perfect choice due to donor-organ shortage and the need of a lifelong immunosuppressive therapy. Therefore, it is necessary to find a new approach to fighting the disease. Several published clinical trials have reported the therapeutic effect of bio-artificial liver (BAL) for liver failure.

Objective

To overview and evaluate the current clinical application and outcomes of extracorporeal BAL support system during the past 15 years.

Methods

Relevant studies were retrieved from PubMed and Cochrane Library databases. Independent assessments and the final consensus decision were performed by three independent reviewers. Acceptable study designs included randomized controlled trials, controlled clinical trials, and case reports. A total of 31 studies were tabulated and critically appraised in terms of characteristics, methods, and outcomes.

Results

There was a trend of falling into the normal ranges with the clinical and biochemical parameters after the BAL treatment. The neurological status of most patients was improved or stabilized during BAL treatment as well. No significant effect on survival could be seen after the BAL treatment.

Conclusions

Although BAL system proved to be a success in some clinical cases reported, it still needs to be improved greatly.
Literature
1.
2.
Shakil AO, Mazariegos GV, Kramer DJ. Fulminant hepatic failure. Surg Clin North Am 1999;79:77–108PubMedCrossRef
3.
Jalan R, Stadlbauer V, Sen S, et al. Natural history of acute decompensation of cirrhosis: the basis of the definition, prognosis and pathophysiology of acute on chronic liver failure. J Hepatology 2006;44:371A
4.
Millis JM, Losanoff JE. Technology insight: liver support systems. Nat Clin Pract Gastroenterol Hepatol 2005;2(398–405):434
5.
Harper AM, Rosendale JD. The UNOS OPTN Waiting List and Donor Registry: 1988–1996. Clin Transpl 1996; 69–90
6.
7.
Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005;42:1364–1372PubMedCrossRef
8.
Yarmush ML, Dunn JC, Tompkins RG. Assessment of artificial liver support technology. Cell Transplant 1992;1:323–341PubMed
9.
10.
Matsumura KN, Guevara GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987;101:99–103PubMed
11.
Demetriou AA, Rozga J, Podesta L, et al. Early clinical experience with a hybrid bioartificial liver. Scand J Gastroenterol Suppl 1995;208:111–117PubMedCrossRef
12.
Coffman KL, Hoffman A, Rosenthal P, Demetriou A, Makowka L. Neurological and psychological sequelae in transplant recipients after bridging with the bioartificial liver. Gen Hosp Psychiatry 1996;18:20S–24SPubMedCrossRef
13.
Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996;24:1446–1451PubMedCrossRef
14.
Chen SC, Mullon C, Kahaku E, et al. Treatment of severe liver failure with a bioartificial liver. Ann N Y Acad Sci 1997;831:350–360PubMedCrossRef
15.
Watanabe FD, Mullon CJ, Hewitt WR, et al. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg 1997;225(484–491):491–494
16.
Watanabe FD, Shackleton CR, Cohen SM, et al. Treatment of acetaminophen-induced fulminant hepatic failure with a bioartificial liver. Transplant Proc 1997;29:487–488PubMedCrossRef
17.
Baquerizo A, Mhoyan A, Kearns-Jonker M, et al. Characterization of human xenoreactive antibodies in liver failure patients exposed to pig hepatocytes after bioartificial liver treatment: an ex vivo model of pig to human xenotransplantation. Transplantation 1999;67:5–18PubMedCrossRef
18.
Detry O, Arkadopoulos N, Ting P, et al. Clinical use of a bioartificial liver in the treatment of acetaminophen-induced fulminant hepatic failure. Am Surg 1999;65:934–938PubMed
19.
Donini A, Baccarani U, Risaliti A, Degrassi A, Bresadola F. Temporary neurological improvement in a patient with acute or chronic liver failure treated with a bioartificial liver device. Am J Gastroenterol 2000;95:1102–1104PubMedCrossRef
20.
Millis JM, Cronin DC, Johnson R, et al. Bioartificial liver support: report of the longest continuous treatment with human hepatocytes. Transplant Proc 2001;33:1935PubMedCrossRef
21.
Millis JM, Cronin DC, Johnson R, et al. Safety of continuous human liver support. Transplant Proc 2001;33:1954PubMedCrossRef
22.
Petrovic LM, Arkadopoulos N, Demetriou AA. Activation of hepatic stellate cells in liver tissue of patients with fulminant liver failure after treatment with bioartificial liver. Hum Pathol 2001;32:1371–1375PubMedCrossRef
23.
Xue YL, Zhao SF, Luo Y, et al. TECA hybrid artificial liver support system in treatment of acute liver failure. World J Gastroenterol 2001;7:826–829PubMed
24.
Demetriou AA, Brown RJ, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004;239(660–667):667–670
25.
Samuel D, Ichai P, Feray C, et al. Neurological improvement during bioartificial liver sessions in patients with acute liver failure awaiting transplantation. Transplantation 2002;73:257–264PubMedCrossRef
26.
Irgang M, Sauer IM, Karlas A, et al. Porcine endogenous retroviruses: no infection in patients treated with a bioreactor based on porcine liver cells. J Clin Virol 2003;28:141–154PubMedCrossRef
27.
van de Kerkhove MP, Di Florio E, Scuderi V, et al. Phase I clinical trial with the AMC-bioartificial liver. Int J Artif Organs 2002;25:950–959PubMed
28.
Mazariegos GV, Patzer JN, Lopez RC, et al. First clinical use of a novel bioartificial liver support system (BLSS). Am J Transplant 2002;2:260–266PubMedCrossRef
29.
Millis JM, Cronin DC, Johnson R, et al. Initial experience with the modified extracorporeal liver-assist device for patients with fulminant hepatic failure: system modifications and clinical impact. Transplantation 2002;74:1735–1746PubMedCrossRef
30.
Morsiani E, Pazzi P, Puviani AC, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002;25:192–202PubMed
31.
Patzer IJ, Lopez RC, Zhu Y, Wang ZF, Mazariegos GV, Fung JJ. Bioartificial liver assist devices in support of patients with liver failure. Hepatobiliary Pancreat Dis Int 1:18–25
32.
Pazzi P, Morsiani E, Vilei MT, et al. Serum bile acids in patients with liver failure supported with a bioartificial liver. Aliment Pharmacol Ther 2002;16:1547–1554PubMedCrossRef
33.
Ding YT, Qiu YD, Chen Z, et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients. World J Gastroenterol 2003;9:829–832PubMed
34.
van de Kerkhove MP, Di Florio E, Scuderi V, et al. Bridging a patient with acute liver failure to liver transplantation by the AMC-bioartificial liver. Cell Transplant 2003;12:563–568PubMed
35.
Qian Y, Lanjuan L, Jianrong H, et al. Study of severe hepatitis treated with a hybrid artificial liver support system. Int J Artif Organs 2003;26:507–513PubMed
36.
Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support–phase I study with primary porcine liver cells. Xenotransplantation 2003;10:460–469PubMedCrossRef
37.
Sauer IM, Zeilinger K, Pless G, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis: treatment of a patient with primary graft non-function. J Hepatol 2003;39:649–653PubMedCrossRef
38.
Baccarani U, Donini A, Sanna A, et al. First report of cryopreserved human hepatocytes based bioartificial liver successfully used as a bridge to liver transplantation. Am J Transplant 2004;4:286–289PubMedCrossRef
39.
Liu Q, Duan ZP, Huang C, Zhao CH. Evaluation of effect of hybrid bioartificial liver using end-stage liver disease model. World J Gastroenterol 2004;10:1379–1381PubMed
40.
Gan JH, Zhou XQ, Qin AL, et al. Hybrid artificial liver support system for treatment of severe liver failure. World J Gastroenterol 2005;11:890–894PubMed
41.
Di Nicuolo G, van de Kerkhove MP, Hoekstra R, et al. No evidence of in vitro and in vivo porcine endogenous retrovirus infection after plasmapheresis through the AMC-bioartificial liver. Xenotransplantation 2005;12:286–292PubMedCrossRef
42.
Lo CM, Fan ST, Liu CL, et al Adult-to-adult living donor liver transplantation using extended right lobe grafts. Ann Surg 1997;226:261–270PubMedCrossRef
43.
Fang S, Qiu YD, Mao L, Shi XL, Yu DC, Ding YT. Differentiation of embryoid-body cells derived from embryonic stem cells into hepatocytes in alginate microbeads in vitro. Acta Pharmacol Sin 2007;28:1924–1930PubMedCrossRef
44.
Shi XL, Qiu YD, Wu XY, et al. In vitro differentiation of mouse bone marrow mononuclear cells into hepatocyte-like cells. Hepatol Res 2005;31:223–231PubMedCrossRef
45.
Shi XL, Qiu YD, Li Q, et al. Hepatocyte-like cells from directed differentiation of mouse bone marrow cells in vitro. Acta Pharmacol Sin 2005;26:469–476PubMedCrossRef
46.
Shi XL, Mao L, Xu BY, et al. Optimization of an effective directed differentiation medium for differentiating mouse bone marrow mesenchymal stem cells into hepatocytes in vitro. Cell Biol Int 2008;32:959–965PubMedCrossRef
47.
Hang H, Shi X, Gu G, Wu Y, Ding Y. A simple isolation and cryopreservation method for adult human hepatocytes. Int J Artif Organs 2009;32:720–727PubMed
48.
Hang H, Shi X, Gu G, Wu Y, Gu J, Ding Y. In vitro analysis of cryopreserved alginate-poly-l-lysine-alginate-microencapsulated human hepatocytes. Liver Int 2010;30:611–622PubMedCrossRef
49.
Gu J, Shi X, Zhang Y, Chu X, Hang H, Ding Y. Establishment of a three-dimensional co-culture system by porcine hepatocytes and bone marrow mesenchymal stem cells in vitro. Hepatol Res 2009;39:398–407PubMedCrossRef
50.
Gu J, Shi X, Zhang Y, Ding Y. Heterotypic interactions in the preservation of morphology and functionality of porcine hepatocytes by bone marrow mesenchymal stem cells in vitro. J Cell Physiol 2009;219:100–108PubMedCrossRef
51.
Gu J, Shi X, Chu X, Zhang Y, Ding Y. Contribution of bone marrow mesenchymal stem cells to porcine hepatocyte culture in vitro. Biochem Cell Biol 2009;87:595–604PubMedCrossRef
52.
Chu XH, Shi XL, Feng ZQ, Gu ZZ, Ding YT. Chitosan nanofiber scaffold enhances hepatocyte adhesion and function. Biotechnol Lett 2009;31:347–352PubMedCrossRef
53.
Chu XH, Shi XL, Feng ZQ, et al. In vitro evaluation of a multi-layer radial-flow bioreactor based on galactosylated chitosan nanofiber scaffolds. Biomaterials 2009;30:4533–4538PubMedCrossRef
Metadata
Title
Systematic review: extracorporeal bio-artificial liver-support system for liver failure
Authors
Jinyang Gu
Xiaolei Shi
Haozhen Ren
Qingxiang Xu
Jun Wang
Jiangqiang Xiao
Yitao Ding
Publication date
01-10-2012
Publisher
Springer-Verlag
Published in
Hepatology International / Issue 4/2012
Print ISSN: 1936-0533
Electronic ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-012-9352-9

Other articles of this Issue 4/2012

Hepatology International 4/2012 Go to the issue

Original Article

Efficacy of peginterferon α-2a and predictors of response in HBeAg-negative, genotype D-naive patients

Original Article

Naturally occurring core immune-escape and carboxy-terminal mutations\truncations in patients with e antigen negative chronic hepatitis B

Original Article

Disadvantages of peginterferon and ribavirin treatment in older patients with chronic hepatitis C: an analysis using the propensity score

Original Article

Low incidence and prevalence of primary biliary cirrhosis in Canterbury, New Zealand: a population-based study

Original Article

Impact of hepatic clearance of endotoxin using endotoxin activity assay

Review Article

Hypoxic hepatitis: a challenging diagnosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits